UK-based AstraZeneca and Eli Lilly have signed an agreement to co-develop a new antibody selective for amyloid-beta 42 (Aβ42) for Alzheimer’s disease (AD) treatment, known as MEDI1814.

At present, Aβ42 is in Phase I trials as a potential disease-modifying treatment for AD.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The latest agreement builds on the existing collaboration between the companies related to AZD3293, a BACE inhibitor in two pivotal Phase III trials.

AstraZeneca IMED Biotech Unit and business development executive vice-president Mene Pangalos said: “We are excited to build on an already productive collaboration with Lilly, which combines the expertise of our two companies, with a new programme focused on the amyloid beta pathway.

"MEDI1814 has a unique mechanism among antibodies in clinical development and could provide a distinct approach to treating Alzheimer’s disease."

“MEDI1814 has a unique mechanism among antibodies in clinical development and could provide a distinct approach to treating Alzheimer’s disease.”

One of the characteristics of AD is forming of plaques in the brain containing the peptide amyloid-beta (Aβ).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new MEDI1814 binds selectively to Aβ42, a form of Aβ associated with the disease, in specific and dose-dependent reduction levels of this peptide, slowing the progression of AD.

Lilly Research Laboratories science and technology executive vice-president Jan Lundberg said: “At Lilly, we recognise the significant burden Alzheimer’s disease places on patients, caregivers and our society and we remain committed to finding ways to change the course of the disease.

“AstraZeneca brings capabilities and expertise and most importantly shares our passion to bring new medicines to patients suffering from this debilitating illness.”